| Year |
Citation |
Score |
| 2023 |
Rose MM, Nassar KW, Sharma V, Schweppe RE. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition. Medical Oncology (Northwood, London, England). 40: 299. PMID 37713162 DOI: 10.1007/s12032-023-02118-2 |
0.338 |
|
| 2023 |
Bolf EL, Beadnell TC, Rose MM, D'Alessandro A, Nemkov T, Hansen KC, Schweppe RE. Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. Cells. 12. PMID 37408209 DOI: 10.3390/cells12101374 |
0.356 |
|
| 2023 |
Hicks HM, Pozdeyev N, Sams SB, Pugazhenthi U, Bales ES, Hofmann MC, McKenna LR, Schweppe RE. Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2. Molecular Cancer Research : McR. PMID 37219859 DOI: 10.1158/1541-7786.MCR-22-1031 |
0.372 |
|
| 2023 |
Rose MM, Espinoza VL, Hoff KJ, Pike LA, Sharma V, Hofmann MC, Tan AC, Pozdeyev N, Schweppe RE. BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer. Cancers. 15. PMID 36672327 DOI: 10.3390/cancers15020378 |
0.406 |
|
| 2020 |
Pozdeyev N, Rose MM, Bowles DW, Schweppe RE. Molecular therapeutics for anaplastic thyroid cancer. Seminars in Cancer Biology. PMID 31991166 DOI: 10.1016/J.Semcancer.2020.01.005 |
0.407 |
|
| 2019 |
Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 6883-6884. PMID 31732665 DOI: 10.1158/1078-0432.Ccr-19-2531 |
0.438 |
|
| 2019 |
Landa-Lopez I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, ... Schweppe RE, et al. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30737244 DOI: 10.1158/1078-0432.Ccr-18-2953 |
0.426 |
|
| 2019 |
Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera D, Landa-Lopez I, Knauf JA, Fagin JA, et al. Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers. Molecular Cancer Research : McR. PMID 30733375 DOI: 10.1158/1541-7786.Mcr-18-1026 |
0.461 |
|
| 2019 |
Kellett M, Kessler B, Mishall K, Sharma V, Schweppe R. SAT-574 Elucidating the Role of Nuclear Focal Adhesion Kinase (FAK) in Thyroid Cancer Journal of the Endocrine Society. 3. DOI: 10.1210/Js.2019-Sat-574 |
0.468 |
|
| 2019 |
Nassar KW, Hintzsche J, Bagby S, Langouet-Astrie C, Samson J, Amato C, Gordon N, Fujita M, Schweppe R, Robinson W, Tan A. Abstract B076: Uncoupling of the cell cycle pathway from the MAPK pathway in BRAF/MEK inhibitor resistant melanoma Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B076 |
0.394 |
|
| 2018 |
Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene. PMID 30531837 DOI: 10.1038/S41388-018-0617-1 |
0.442 |
|
| 2018 |
Oweida AJ, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen BR, Pozdeyev N, Schweppe RE, Karam SD. Hypofractionated radiotherapy is superior to conventional fractionation in an orthotopic model of anaplastic thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. PMID 29774792 DOI: 10.1089/Thy.2017.0706 |
0.354 |
|
| 2018 |
Pozdeyev N, Gay L, Sokol ES, Hartmaier RJ, Deaver KE, Davis SN, French JD, Vanden Borre P, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29615459 DOI: 10.1158/1078-0432.Ccr-18-0373 |
0.356 |
|
| 2018 |
Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis. 7: 23. PMID 29487290 DOI: 10.1038/s41389-017-0015-5 |
0.446 |
|
| 2018 |
Kiseljak-Vassiliades K, Zhang Y, Bagby S, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe R, Somerset HL, Pitts TM, et al. Development of new preclinical models to advance adrenocortical carcinoma research. Endocrine-Related Cancer. PMID 29371329 DOI: 10.1530/Erc-17-0447 |
0.368 |
|
| 2018 |
Oweida AJ, Phan A, Vancourt B, Robin T, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Abstract 4168: Radioresistant anaplastic thyroid cancers display a unique gene signature and respond to hypofractionated radiotherapy Tumor Biology. DOI: 10.1158/1538-7445.Am2018-4168 |
0.376 |
|
| 2017 |
Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE. Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget. 8: 103014-103031. PMID 29262541 DOI: 10.18632/Oncotarget.20488 |
0.474 |
|
| 2016 |
Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget. PMID 27322211 DOI: 10.18632/Oncotarget.10010 |
0.307 |
|
| 2016 |
Kessler BE, Sharma V, Zhou Q, Jing X, Pike LA, Kerege AA, Sams SB, Schweppe RE. FAK Expression, Not Kinase Activity, is a Key Mediator of Thyroid Tumorigenesis and Pro-tumorigenic Processes. Molecular Cancer Research : McR. PMID 27259715 DOI: 10.1158/1541-7786.Mcr-16-0007 |
0.503 |
|
| 2016 |
Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE. The Mitogen Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor, Dasatinib, in Thyroid Cancer. Molecular Cancer Therapeutics. PMID 27222538 DOI: 10.1158/1535-7163.Mct-15-0702 |
0.492 |
|
| 2015 |
Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget. 6: 10175-94. PMID 25868388 DOI: 10.18632/Oncotarget.3391 |
0.387 |
|
| 2015 |
Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Hormones & Cancer. 6: 87-99. PMID 25800363 DOI: 10.1007/S12672-015-0219-0 |
0.438 |
|
| 2015 |
Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. The Journal of Clinical Endocrinology and Metabolism. 100: E243-52. PMID 25427145 DOI: 10.1210/Jc.2014-2624 |
0.401 |
|
| 2014 |
Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. The Journal of Clinical Endocrinology and Metabolism. 99: E1436-44. PMID 24758177 DOI: 10.1210/Jc.2013-3636 |
0.441 |
|
| 2014 |
Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. The Journal of Clinical Endocrinology and Metabolism. 99: E1368-75. PMID 24712572 DOI: 10.1210/Jc.2014-1171 |
0.403 |
|
| 2013 |
Schweppe RE. Thyroid cancer cell line misidentification: an update. The Journal of Clinical Endocrinology and Metabolism. 98: 956-7. PMID 23472230 DOI: 10.1210/Jc.2012-4182 |
0.382 |
|
| 2012 |
Schweppe RE. Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets. Frontiers in Endocrinology. 3: 81. PMID 22723793 DOI: 10.3389/Fendo.2012.00081 |
0.457 |
|
| 2012 |
Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3580-91. PMID 22586301 DOI: 10.1158/1078-0432.Ccr-11-3359 |
0.469 |
|
| 2011 |
Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, Haugen BR. PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells. Ppar Research. 2011: 171765. PMID 22194735 DOI: 10.1155/2011/171765 |
0.457 |
|
| 2011 |
Schweppe RE, Haugen BR. Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology. Thyroid : Official Journal of the American Thyroid Association. 21: 941-4. PMID 21877921 DOI: 10.1089/Thy.2011.2109.Ed |
0.413 |
|
| 2010 |
Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Molecular Cancer. 9: 117. PMID 20492683 DOI: 10.1186/1476-4598-9-117 |
0.451 |
|
| 2009 |
Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G. Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells. Endocrine Reviews. 30: 932. PMID 28199516 DOI: 10.1210/edrv.30.7.9986 |
0.339 |
|
| 2009 |
Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid : Official Journal of the American Thyroid Association. 19: 825-35. PMID 19500021 DOI: 10.1089/Thy.2008.0362 |
0.669 |
|
| 2009 |
Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Molecular Cell. 34: 115-31. PMID 19362540 DOI: 10.1016/J.Molcel.2009.03.007 |
0.457 |
|
| 2009 |
Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 94: 2199-203. PMID 19293266 DOI: 10.1210/Mend.23.5.9999 |
0.47 |
|
| 2008 |
Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. The Journal of Clinical Endocrinology and Metabolism. 93: 4331-41. PMID 18713817 DOI: 10.1210/Jc.2008-1102 |
0.392 |
|
| 2006 |
Schweppe RE, Cheung TH, Ahn NG. Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses. The Journal of Biological Chemistry. 281: 20993-1003. PMID 16735500 DOI: 10.1074/Jbc.M604208200 |
0.372 |
|
| 2003 |
Tentler JJ, Bradford AP, Schweppe RE, Gutierrez-Hartmann A. Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells. Endocrine. 20: 3-12. PMID 12668863 DOI: 10.1385/Endo:20:1-2:3 |
0.624 |
|
| 2003 |
Schweppe RE, Melton AA, Brodsky KS, Aveline LD, Resing KA, Ahn NG, Gutierrez-Hartmann A. Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter. The Journal of Biological Chemistry. 278: 16863-72. PMID 12618435 DOI: 10.1074/Jbc.M213063200 |
0.624 |
|
| 2002 |
Vaish NK, Dong F, Andrews L, Schweppe RE, Ahn NG, Blatt L, Seiwert SD. Monitoring post-translational modification of proteins with allosteric ribozymes. Nature Biotechnology. 20: 810-5. PMID 12118241 DOI: 10.1038/Nbt719 |
0.407 |
|
| 2001 |
Jackson TA, Schweppe RE, Koterwas DM, Bradford AP. Fibroblast growth factor activation of the rat PRL promoter is mediated by PKCdelta. Molecular Endocrinology (Baltimore, Md.). 15: 1517-28. PMID 11518800 DOI: 10.1210/Mend.15.9.0683 |
0.433 |
|
| 2001 |
Schweppe RE, Gutierrez-Hartmann A. Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter. Nucleic Acids Research. 29: 1251-60. PMID 11222776 DOI: 10.1093/Nar/29.5.1251 |
0.605 |
|
| 1999 |
Johnson TK, Schweppe RE, Septer J, Lewis RE. Phosphorylation of B-Myb regulates its transactivation potential and DNA binding Journal of Biological Chemistry. 274: 36741-36749. PMID 10593981 DOI: 10.1074/Jbc.274.51.36741 |
0.374 |
|
| 1997 |
Schweppe RE, Frazer-Abel AA, Gutierrez-Hartmann A, Bradford AP. Functional components of fibroblast growth factor (FGF) signal transduction in pituitary cells. Identification of FGF response elements in the prolactin gene. The Journal of Biological Chemistry. 272: 30852-9. PMID 9388230 DOI: 10.1074/Jbc.272.49.30852 |
0.648 |
|
| Show low-probability matches. |